bioSyntagma, Inc, leveraged our molecular diagnostics expertise, and collaborated with Takara Bio USA, Inc., to develop and validate a new high-throughput method for detecting SARS-CoV-2 (COVID-19). The method employs automation technology and reagents from Takara BUSA to detect viral RNA via real-time PCR and will enable rapid, large-scale testing of the virus during this global pandemic.
Click here to learn more.
bioSyntagma is a precision medicine company that enables advanced biomarker discovery and patient screening. Its suite of AI-enabled technologies enables comprehensive mapping of cancer patient biopsies (spatial, multi-omic) so that patients can be matched with relevant therapies and provided recommendations to avoid acquiring drug resistance. bioSyntagma serves the needs of clinicians, academic researchers, and drug developers to advance the implementation of precision medicine for cancer treatment.The founders are from Arizona State University and members of the Center for Entrepreneurial Innovation.